ERBB2 and breast cancer: Increasing evidence reported the effectiveness of continuous blockade of HER2 by trastuzumab, including two retrospective studies which have shown the efficacy of re-treatment regimen with trastuzumab in HER2-positive breast cancer, reporting an OS of 48.2 months [17] and two-year OS rate of 60.0% [18].